# A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

> **NCT02466815** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-42756493 Current Clinical Formulation (G-018)
- **DRUG:** JNJ-42756493 Prototype Formulation I (G-025)
- **DRUG:** JNJ-42756493 Prototype Formulation II (G-025)

## Key facts

- **NCT ID:** NCT02466815
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02466815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02466815, "A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02466815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*